Mitoquinone mesylate

Last updated
Mitoquinone mesylate
Mitoquinone mesylate skeletal.svg
Clinical data
Trade names MitoQ
Identifiers
  • 10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium methanesulfonate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C38H47O7PS
Molar mass 678.82 g·mol−1
3D model (JSmol)
  • CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)[O-]
  • InChI=1S/C37H44O4P.CH4O3S/c1-29-33(35(39)37(41-3)36(40-2)34(29)38)27-19-8-6-4-5-7-9-20-28-42(30-21-13-10-14-22-30,31-23-15-11-16-24-31)32-25-17-12-18-26-32;1-5(2,3)4/h10-18,21-26H,4-9,19-20,27-28H2,1-3H3;1H3,(H,2,3,4)/q+1;/p-1
  • Key:GVZFUVXPTPGOQT-UHFFFAOYSA-M

Mitoquinone mesylate (MitoQ) is a synthetic analogue of coenzyme Q10 which has antioxidant effects. It was first developed in New Zealand in the late 1990s. [1] It has significantly improved bioavailability and improved mitochondrial penetration compared to coenzyme Q10, [2] [3] and has shown potential in a number of medical indications, [4] [5] [6] [7] being widely sold as a dietary supplement. [8] [9]

A 2014 review found insufficient evidence for the use of mitoquinone mesylate in Parkinson's disease and other movement disorders. [10]

A 2025 British study found that diabetes patients who took daily mitoquinone, a widely available antioxidant, as well as their standard treatment had healthier hearts after four months than those not given the supplement. Mitoquinone was able to reverse the early signs of diabetes-related heart failure over the course of the study. [11]

See also

References

  1. ↑ USabandoned 20060229278,Taylor K, Smith R,"Mitoquinone derivatives used as mitochondrially targeted antioxidants.",published 12 October 2006, assigned to Antipodean Pharmaceuticals Inc
  2. ↑ Battogtokh G, Choi YS, Kang DS, Park SJ, Shim MS, Huh KM, et al. (October 2018). "Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives". Acta Pharmaceutica Sinica B. 8 (6): 862–880. doi:10.1016/j.apsb.2018.05.006. PMC   6251809 . PMID   30505656.
  3. ↑ Gutierrez-Mariscal FM, Arenas-de Larriva AP, Limia-Perez L, Romero-Cabrera JL, Yubero-Serrano EM, López-Miranda J (October 2020). "Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases". International Journal of Molecular Sciences. 21 (21): 7870. doi: 10.3390/ijms21217870 . PMC   7660335 . PMID   33114148.
  4. ↑ Silva FS, Simoes RF, Couto R, Oliveira PJ (2016). "Targeting Mitochondria in Cardiovascular Diseases". Current Pharmaceutical Design. 22 (37): 5698–5717. doi:10.2174/1381612822666160822150243. PMID   27549376.
  5. ↑ Kezic A, Spasojevic I, Lezaic V, Bajcetic M (2016). "Mitochondria-Targeted Antioxidants: Future Perspectives in Kidney Ischemia Reperfusion Injury". Oxidative Medicine and Cellular Longevity. 2016: 2950503. doi: 10.1155/2016/2950503 . PMC   4894993 . PMID   27313826.
  6. ↑ Oliver DM, Reddy PH (April 2019). "Small molecules as therapeutic drugs for Alzheimer's disease". Molecular and Cellular Neurosciences. 96: 47–62. doi:10.1016/j.mcn.2019.03.001. PMC   6510253 . PMID   30877034.
  7. ↑ Ismail H, Shakkour Z, Tabet M, Abdelhady S, Kobaisi A, Abedi R, et al. (October 2020). "Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone". Antioxidants. 9 (10): 943. doi: 10.3390/antiox9100943 . PMC   7601591 . PMID   33019512.
  8. ↑ Braakhuis AJ, Nagulan R, Somerville V (2018). "The Effect of MitoQ on Aging-Related Biomarkers: A Systematic Review and Meta-Analysis". Oxidative Medicine and Cellular Longevity. 2018: 8575263. doi: 10.1155/2018/8575263 . PMC   6079400 . PMID   30116495.
  9. ↑ Thoma A, Akter-Miah T, Reade RL, Lightfoot AP (August 2020). "Targeting reactive oxygen species (ROS) to combat the age-related loss of muscle mass and function". Biogerontology. 21 (4): 475–484. doi:10.1007/s10522-020-09883-x. PMC   7347670 . PMID   32447556.
  10. ↑ Liu J, Wang LN (January 2014). "Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone". CNS Drugs. 28 (1): 63–8. doi:10.1007/s40263-013-0124-4. PMID   24242074. S2CID   207486107.
  11. ↑ https://medicalxpress.com/news/2025-06-counter-supplement-heart-disease-diabetes.html Kaamya Mehta, British Heart Foundation article about mitoquinone could prevent heart disease in type 2 diabetes patients


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.